Background. The Antibody-mediated Prevention (AMP) trials (HVTN 704/ HPTN 085 and HVTN 703/HPTN 081) are the first efficacy trials to evaluate whether VRC01, a broadly neutralizing antibody (bnAb) that targets CD4 binding site of HIV envelope, prevents HIV acquisition in uninfected individuals. In these ongoing trials, 10 intravenous (IV) infusions of VRC01 are given every 8 weeks over a period of 2 years. We report on interim operational feasibility, enrollment and safety.
Background. Pre-exposure prophylaxis (PrEP) effectively reduces HIV acquisition, but its efficacy depends on continued engagement through periods of high and low risk. Persistence in HIV prevention care has been low in real-world settings. In our program, 32% of patients are lost to care after their first visit and only 35% of patients are retained at their planned third visit. Reasons for low persistence in care are poorly described.
Methods. We identified all MSM who started PrEP between July 2015 and June 2018 at a sexual health clinic in an urban academic medical center in New York and had not had a visit in ≥6 months. We called patients between July 2018 and January 2019; those who were English speaking were given the option to complete an online questionnaire about current PrEP status, reasons for disengagement, and social and behavioral determinants of health (SBDH).
Results. Up to 710 patients were eligible for the study; over 700 calls were made. 125 participants agreed to participate and 57 (46%) completed the questionnaire. 24 patients (42%) were still actively taking PrEP. The most common reasons for starting PrEP were fear of getting HIV (58%), high self-perceived HIV risk (28%), and recommendations from friends (26%). Among those no longer taking PrEP, the most common reasons for discontinuation were cost/insurance issues (32%), lower perceived HIV risk (18%), concern about long-term side effects (12%), and trouble attending every-3month appointments (12%). For those stopping due to lower perceived risk, 40% were in a monogamous relationship, 60% were less sexually active, and 20% always used a condom or did not engage in receptive anal intercourse. 56% of patients had at least 1 major life event in the preceding 3 months, including loss of a job (25%), breakup with a partner (12%), illness or death of a family member (11%), or unstable housing (8%). 47% used drugs or alcohol before sex in the past month including 39% not on PrEP.
Conclusion. Reasons for engagement, disengagement, and re-engagement are highly variable at the individual level. Cost and insurance issues were common in spite if clinic resources available to cover the cost of visits and medications. Life trauma was common. Individualized interventions to address SBDH may be required to engage and retain individuals in HIV prevention care.
Disclosures. 
Background.
Despite the clear preventive benefits of HIV Pre-Exposure Prophylaxis (PrEP), uptake among populations at highest risk of HIV acquisition has been limited by lack of health insurance and access to care. In March 2018 we opened a free PrEP clinic for those without insurance. We provide HIV prevention services, following the CDC guidelines, with PrEP case manager navigation, medical management, and medication for at-risk individuals free of charge.
Methods. Half-day clinics were organized on a twice-monthly basis with supervision provided by two infectious disease specialists and several other licensed providers/ fellows, with supporting case managers and medical assistants. Medical students were enlisted to help organize and manage patient visits. All patient visits were preceded by discussion with case managers to document insurance status, followed by a sexual history and general physical examination by medical students and supervisory licensed providers. We performed all laboratory testing, diagnostics, and follow-up visits per CDC guidelines.
Results. From March 2018 to 2019 self-identified at-risk patients scheduled an appointment; 157 unique patients were seen and all deemed eligible for PrEP per CDC guidelines. Of those eligible for PrEP, 140 (89%) received a prescription and started emtricitabine/tenofovir and 115 (73%) remain in care with ≥2 visits completed. Of the 25 no longer in care at our clinic, 6 have insurance or Medicaid (2 continue to be seen in our insured PrEP Clinic), 1 reports no HIV risk factors, and 1 is over-income for pharmacy patient assistance. Patients enrolled in clinic are largely male (145, 92%); 74% age ≤ 34, a disproportionate fraction belonging to a minority racial/ethnic group (67, 43%), with a majority Latinx (60, 38%). A total of 48 STI cases were identified, mostly rectal chlamydia, rectal and pharyngeal gonorrhea 39 (81%), and 9 (19%) cases of syphilis, and no new HIV or HCV infections. At the first visit, 17% of our patients have an STI and at subsequent visits 22% have a new STI.
Conclusion. Implementation of a free PrEP clinic for uninsured patients is a feasible and effective strategy to reach key populations at risk for HIV. STI rates are high in our population and increased after starting PrEP.
